includ
realtim
polymeras
chain
reaction
pcr
nucleic
acid
sequencebas
amplif
nasba
loopmedi
isotherm
amplif
lamp
multiplex
pcr
fluidic
microarray
dna
chip
recent
diagnost
advanc
issuanc
guidanc
document
analytespecif
reagent
asr
us
food
drug
administr
fda
primer
probe
develop
packag
sold
asr
sinc
reagent
longer
commerci
avail
submit
receiv
fda
approv
vitro
diagnost
devic
primer
probe
reagent
sold
separ
without
recommend
use
articl
discuss
commerci
avail
molecular
method
perform
characterist
detect
respiratori
virus
influenza
virus
remain
signific
caus
ari
everi
year
despit
avail
vaccin
increas
effort
achiev
target
vaccin
rate
virus
estim
caus
hospit
per
year
children
nation
us
outpati
visit
associ
influenza
report
approxim
time
high
hospit
rate
children
month
month
month
age
respect
substanti
burden
influenzaassoci
hospit
death
ascertain
sever
studi
sever
affect
older
year
also
signific
adult
hospit
rate
determin
equal
among
children
younger
year
antigen
assay
detect
influenza
commonli
avail
likelihood
neg
result
use
assay
increas
significantli
increas
age
patient
wherea
viru
cultur
revers
transcriptas
pcr
rtpcr
older
patient
rtpcr
cultur
necessari
avoid
falseneg
result
molecular
method
detect
influenza
virus
describ
earli
variou
target
includ
matrix
ha
n
gene
use
first
commerci
avail
assay
hexaplex
assay
prodess
inc
waukesha
wisconsin
rtpcr
assay
employ
enzym
hybrid
postamplif
detect
assay
technic
demand
requir
postamplif
purif
also
expens
took
hour
complet
assay
analyt
sensit
copi
influenza
copi
influenza
b
set
standard
detect
influenza
virus
sinc
redesign
fdaapprov
multiplex
realtim
rtpcr
assay
prodess
inc
detect
influenza
gene
influenza
b
gene
respiratori
syncyti
viru
rsv
polymeras
gene
perform
use
magna
pure
lc
instrument
roch
diagnost
corpor
indianapoli
indiana
nuclisen
easymag
system
biomerieux
inc
durham
north
carolina
extract
amplif
detect
smartcycl
system
cepheid
sunnyval
california
accord
manufactur
clinic
sensit
specif
influenza
influenza
b
respect
analyt
sensit
tissu
cultur
infecti
dose
tcid
ml
virus
xtag
respiratori
viru
panel
luminex
molecular
diagnost
toronto
canada
also
fdaapprov
multiplex
panel
detect
respiratori
virus
capabl
detect
respiratori
virus
fdaapprov
detect
rsv
parainfluenza
metapneumoviru
adenoviru
rhinoviru
addit
influenza
assay
employ
multiplex
pcr
fluid
microspherebas
array
detect
luminex
xmap
system
flow
cytomet
report
clinic
sensit
influenza
analyt
sensit
tcid
addit
fdaapprov
assay
asr
influenza
commerci
avail
eragen
bioscienc
madison
wisconsin
cepheid
sunnyval
california
assay
perform
claim
made
manufactur
littl
inform
publish
regard
perform
literatur
replet
homebrew
inhous
develop
assay
detect
influenza
use
variou
amplif
methodolog
evalu
homebrew
assay
asr
analyt
sensit
tcid
desir
comparison
antigen
assay
cultur
clinic
sensit
easili
attain
along
detect
addit
virus
miss
cultur
altern
pcr
methodolog
confirm
true
posit
specimen
pcrbase
respiratori
viru
assay
demonstr
significantli
better
sensit
antigen
detect
assay
enzym
immunoassay
adult
may
falseneg
rate
immunofluoresc
assay
also
better
sensit
cultur
children
particularli
adult
sever
manufactur
assay
avail
research
use
ruo
kit
sever
kit
multicodeplx
eragen
bioscienc
inc
resplex
ii
panel
qiagen
inc
valencia
california
employ
luminex
system
report
perform
claim
similar
xtag
respiratori
viru
panel
autom
solid
film
microarray
assay
also
develop
none
commerci
avail
respiratori
syncyti
viru
rsv
accept
import
respiratori
viral
pathogen
infant
young
children
long
recogn
caus
highest
number
pediatr
hospit
lri
estim
hospit
annual
children
younger
year
subsequ
studi
shed
light
enorm
outpati
emerg
room
burden
ill
associ
viru
also
thu
addit
caus
annual
winter
epidem
bronchiol
pneumonia
young
children
requir
hospit
rsv
also
lead
signific
outpati
diseas
viru
establish
import
pathogen
respiratori
diseas
elderli
highrisk
adult
like
influenza
hexaplex
assay
first
commerci
avail
assay
detect
rsv
analyt
sensit
copi
clinic
sensit
specif
respect
children
mix
popul
adult
children
redesign
fdaapprov
multiplex
realtim
rtpcr
assay
accord
manufactur
analyt
sensit
tcid
clinic
sensit
specif
respect
studi
earlier
version
perform
pediatr
sampl
assay
sensit
specif
assay
sensit
compar
enzym
immunoassay
cultur
fdaapprov
xtag
respiratori
viru
panel
analyt
sensit
tcid
reaction
clinic
sensit
asr
commerci
avail
cepheid
analyt
sensit
copi
per
reaction
clinic
sensit
compar
enzym
immunoassay
increas
posit
patient
howev
seen
asr
increas
posit
rate
rtpcr
consist
report
other
compar
antigen
detect
method
inhous
assay
detect
rsv
develop
use
f
n
l
polymeras
gene
target
studi
report
sensit
antigen
assay
low
sensit
cultur
util
nucleic
acid
amplif
assay
increas
detect
posit
patient
rtpcr
increas
sensit
rtpcr
report
immunocompromis
adult
also
nucleic
acid
amplif
assay
sensit
method
detect
rsv
regardless
popul
test
specimen
low
viral
load
seen
adult
immunocompromis
patient
like
antigenneg
rtpcr
posit
multicodeplx
ruo
assay
report
perform
claim
similar
xtag
respiratori
viru
panel
resplex
ii
panel
ruo
assay
significantli
lower
sensit
autom
microarray
develop
rsv
also
human
parainfluenzavirus
type
import
caus
ari
age
group
caus
upper
respiratori
tract
infect
croup
children
adult
lower
respiratori
tract
infect
infant
young
children
elderli
immunocompromis
chronic
medic
condit
hpiv
second
rsv
caus
hospit
lri
children
differ
subtyp
associ
distinct
clinic
syndrom
age
group
season
clinic
signific
epidemiolog
fourth
type
although
discov
year
ago
understood
less
well
three
type
fdaapprov
assay
detect
xtag
respiratori
viru
panel
analyt
sensit
tcid
reaction
clinic
sensit
respect
multicodeplx
ruo
assay
report
sensit
resplex
ii
panel
ruo
assay
significantli
lower
sensit
evalu
suffer
low
number
posit
sampl
particularli
assay
prodess
also
ruo
assay
howev
publish
report
perform
hexaplex
assay
report
sensit
parainfluenzavirus
increas
detect
number
posit
patient
suggest
sensit
cultur
sensit
natur
achiev
proper
primer
probe
condit
inhous
develop
assay
report
similar
find
studi
compar
inhous
assay
direct
fluoresc
antigen
report
sensit
antigen
detect
rtpcr
nucleic
acid
amplif
assay
prefer
direct
fluoresc
antigen
assay
cultur
detect
parainfluenzavirus
adenovirus
ubiquit
distribut
virus
common
caus
selflimit
respiratori
ocular
gastrointestin
ill
outbreak
immunocompet
children
unit
state
militari
recruit
report
caus
sever
prolong
sometim
fatal
ill
immunocompromis
host
spectrum
diseas
latter
popul
includ
pneumonia
hepat
hemorrhag
cystiti
coliti
pancreat
myocard
meningoenceph
dissemin
diseas
depend
host
viru
characterist
seven
speci
g
serotyp
describ
associ
distinct
clinic
syndrom
involv
specif
organ
system
nucleic
acid
amplif
assay
detect
adenoviru
detect
hexon
gene
although
assay
target
fiber
gene
report
xtag
respiratori
viru
panel
fdaapprov
assay
detect
adenoviru
respiratori
specimen
analyt
sensit
tcid
reaction
clinic
kehl
kumar
sensit
adenoviru
also
includ
multicodeplx
ruo
assay
report
sensit
howev
small
number
posit
sampl
test
inhous
develop
assay
target
hexon
gene
clinic
sensit
indirect
immunofluoresc
antigen
test
sensit
studi
also
show
sever
log
differ
concentr
virus
specimen
posit
pcr
alon
compar
specimen
posit
immunofluoresc
antigen
test
pcr
welldesign
nucleic
acid
amplif
assay
detect
adenoviru
serotyp
sensit
method
detect
adenoviru
wide
spectrum
diseas
valid
assay
wide
rang
specimen
type
import
human
metapneumoviru
hmpv
wellstudi
new
virus
discov
sinc
establish
signific
respiratori
pathogen
children
adult
report
second
common
caus
agent
bronchiol
infant
contribut
substanti
burden
upper
respiratori
tract
infect
includ
acut
otiti
media
older
children
viru
common
caus
mild
upper
respiratori
infect
uri
asymptomat
ill
healthi
adult
sever
ill
result
hospit
includ
icu
admiss
describ
elderli
adult
underli
condit
immunocompromis
xtag
respiratori
viru
panel
fdapprov
assay
detect
hmpv
respiratori
specimen
analyt
sensit
tcid
ml
clinic
sensit
detect
significantli
posit
direct
immunofluoresc
assay
prodess
fdaapprov
realtim
rtpcr
accord
manufactur
analyt
sensit
tcid
clinic
sensit
compar
previous
avail
nuclisen
asr
assay
show
excel
sensit
multicodeplx
ruo
assay
report
sensit
howev
small
number
posit
sampl
test
resplex
ii
panel
ruo
assay
significantli
lower
sensit
report
inhous
develop
assay
metapneumoviru
suffer
low
number
posit
sampl
lack
compar
assay
virus
previous
consid
upper
respiratori
pathogen
rhinovirus
coronavirus
cov
recent
report
play
role
respiratori
hospit
also
rhinovirus
classic
associ
uri
includ
common
cold
otiti
media
sinus
caus
ill
throughout
year
peak
earli
fall
spring
clinic
signific
precis
role
rhinovirus
lri
healthi
host
need
investig
assay
approv
fda
detect
rhinoviru
three
assay
employ
multiplex
pcr
fluid
microspherebas
array
detect
luminex
xmap
system
includ
rhinoviru
target
xtag
respiratori
viru
panel
analyt
sensit
tcid
ml
clinic
sensit
specif
respect
multicodeplx
also
sensit
falseposit
result
inhous
develop
assay
employ
nasba
rtpcr
show
sensit
respect
assay
significantli
sensit
cultur
appear
rhinovirus
detect
use
molecular
method
posit
result
util
nucleic
acid
amplif
assay
confirm
cultur
sequenc
data
differ
rhinoviru
serotyp
current
circul
strain
need
improv
primer
coverag
five
cov
speci
describ
caus
human
diseas
describ
caus
agent
common
cold
lri
young
children
elderli
adult
sever
acut
respiratori
syndrom
cov
sarscov
caus
agent
outbreak
sar
worldwid
found
circul
peopl
sinc
two
new
cov
howev
describ
respect
virus
although
newli
discov
subsequ
shown
circul
peopl
long
time
new
cov
associ
uri
lri
assay
approv
fda
detect
cov
xtag
respiratori
viru
panel
fdaapprov
cov
use
studi
epidemiolog
viru
analyt
sensit
genom
equival
multicodeplx
ruo
assay
includ
cov
except
publish
report
suffer
inadequ
number
posit
specimen
assess
perform
bocaviru
new
viru
discov
use
nonspecif
nucleic
acid
amplif
techniqu
detect
sampl
patient
acut
respiratori
symptom
limit
sequenc
data
avail
bocaviru
make
select
conserv
region
difficult
detect
use
realtim
pcr
method
howev
use
detect
bocaviru
although
increas
number
studi
report
detect
bocaviru
patient
respiratori
ill
determin
causal
relationship
lri
difficult
given
high
rate
codetect
respiratori
pathogen
prolong
detect
patient
rais
question
possibl
persist
prolong
infect
lack
cell
cultur
serodiagnost
method
could
help
differenti
true
infect
nucleic
acid
detect
import
yet
underemphas
aspect
nucleic
acid
amplificationbas
diagnost
method
extract
system
use
detect
respiratori
virus
perform
adequ
without
specimen
extract
respiratori
virus
predominantli
rna
genom
howev
adenoviru
bocaviru
dna
virus
includ
diagnost
screen
assay
extract
contain
total
nucleic
acid
use
type
applic
differ
system
differ
abil
recov
rna
dna
total
nucleic
acid
determin
perform
characterist
laboratorydevelop
assay
assay
employ
asr
perform
characterist
extract
system
also
must
document
fdaapprov
kit
approv
use
specif
method
extract
use
differ
method
laboratori
requir
user
perform
complet
revalid
perform
characterist
kit
numer
report
literatur
laboratorydevelop
assay
detect
respiratori
virus
mani
report
includ
target
gene
includ
amino
acid
posit
includ
silico
coverag
rate
primer
probe
describ
amplif
detect
format
employ
determin
number
mismatch
permiss
still
retain
target
detect
import
check
coverag
regularli
ensur
newli
emerg
strain
detect
pcr
rtpcr
commonli
use
nucleic
acid
amplif
method
detect
respiratori
virus
mani
employ
primer
singl
target
design
multiplex
assay
requir
good
primer
design
extens
valid
document
lack
interfer
report
inhous
develop
multiplex
assay
commerci
avail
product
implement
touchdown
amplif
protocol
involv
step
reduct
anneal
temperatur
introduc
advantag
specif
bind
allow
multiplex
common
amplif
protocol
isotherm
amplif
procedur
nasba
lamp
also
use
detect
respiratori
virus
realtim
detect
elimin
manipul
amplifi
product
minim
problem
associ
amplicon
contamin
carryov
falseposit
reaction
also
decreas
turnaround
time
assay
realtim
detect
often
employ
target
specif
probe
thu
also
increas
specif
assay
variou
probe
chemistri
label
avail
choic
probe
format
label
often
determin
detect
platform
employ
spectral
overlap
fluoresc
label
howev
also
limit
number
multiplex
target
detect
option
thu
realtim
detect
extrem
use
howev
adapt
broad
rang
multianalyt
screen
improv
amplif
effici
expand
multiplex
abil
postamplif
detect
must
employ
postamplif
detect
requir
handl
amplicon
significantli
increas
turn
around
time
advantag
abil
detect
multipl
pathogen
singl
assay
larg
number
virus
capabl
caus
similar
symptom
patient
diagnosi
respiratori
tract
infect
seem
uniqu
suit
applic
solidphas
microarray
allow
larg
number
probe
employ
also
may
allow
variabl
hybrid
condit
detect
larg
number
target
mismatch
target
accomplish
suspens
microarray
employ
liquid
phase
bead
conjug
array
allow
rapid
hybrid
condit
flexibl
assay
design
bead
makeup
modifi
easili
although
autom
microarray
system
approv
fda
system
potenti
decreas
hand
technologist
time
howev
current
cost
turnaround
time
